About L2MTech
L2MTech is a Healthcare company based in Bonn (Germany) founded in 2017. It manufactures and distributes cardiovascular stents and catheters globally. It operates on a B2B model. Its Indian entity L2mtech India Private Limited reported revenue of ₹88.9 Lakh. L2MTech offers products and services including PearlFlow, LimusTrack, FlexiTrack-018 PTA Catheter, FlexiTrack-035 PTA Catheter, and PearlFlow NS. Its focus areas include Medical Devices, Cardiovascular and Stents and Catheters. Similar companies include Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group and 5 more; 8 of its 10 listed similar companies have raised funding.
Company details
L2MTech GmbH is a multinational company based in Bonn, Germany, specializing in designing, developing, manufacturing, and distributing medical devices. They focus on products such as stents and catheters for treating peripheral artery disease and other cardiovascular conditions. The company serves healthcare establishments worldwide through B2B channels, emphasizing innovative solutions for medical interventions.
- Headquarters Bonn, Germany
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website l2mtech.de
- Legal Name L2mtech India Private Limited
- Date of Incorporation 19 Oct, 2019
- Jurisdiction Ratlam, Madhya Pradesh, India
- Annual Revenue₹88.9 Lakh
FY 2024 · -55% YoY
- Net Loss-₹26.2 Lakh
FY 2024 · -29% margin
- EBITDA-₹5.2 Lakh
FY 2024 · -6% margin
Associated legal entities of L2MTech
L2MTech operates through L2mtech India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| L2mtech India Private Limited CIN U33119MP2019PTC049885 | Active | 19 Oct 2019 | Ratlam, Madhya Pradesh | ₹0.9 Cr | – | 3 | View details |
Products & Services of L2MTech
L2MTech offers a comprehensive portfolio of products and services, including PearlFlow, LimusTrack, FlexiTrack-018 PTA Catheter, FlexiTrack-035 PTA Catheter, and PearlFlow NS.
Self-Expandable Nitinol Peripheral Stent for artery disease treatment.
Paclitaxel Eluting Coronary Balloon to minimize restenosis risks.
Peripheral catheter for Infrapopliteal arteries interventions.
Designed for multiple peripheral intervention challenges.
Nitinol Peripheral Stent system addressing artery disease.
Coronary Balloon with excipient for enhanced drug uptake.
Board of directors of L2mtech India Private Limited (L2MTech)
L2mtech India Private Limited is the primary company behind L2MTech. The board of L2mtech India Private Limited currently have 3 directors; the longest-serving is Raj Kumar Mamtani, appointed in 2019. 4 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Raj Kumar Mamtani DIN 08592342 | Director | 19 Oct 2019 | 7 yrs | L2mtech India Private Limited |
| Lalit Mamtani DIN 01666692 | Director | 29 Mar 2023 | 3 yrs 6 mo | L2mtech India Private Limited |
| Mahek Mamtani DIN 06907769 | Director | 29 Mar 2023 | 3 yrs 6 mo | L2mtech India Private Limited |
Financials of L2MTech
Figures of L2mtech India Private Limited, the primary company behind L2MTech, for FY 2024. Revenue was ₹88.9 Lakh (-55% year on year). Net loss was -₹26.2 Lakh (-29% margin). EBITDA was -₹5.2 Lakh (-6% margin). Revenue has grown at a compounded annual rate of +7% over three years.
- ₹88.9 LakhRevenue · FY 2024 · -55% YoY
- -₹26.2 LakhNet loss · -29% margin
- -₹5.2 LakhEBITDA · -6% margin
- ₹5 LakhPaid-up capital
- +7%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of L2mtech India Private Limited are on its company page.
Detailed financial statements for L2MTech
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Similar companies to L2MTech
L2MTech has 10 listed similar companies in our database, 8 of them funded. They include Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| straumann.com | 1954 | Basel, Switzerland | – | – | Dental implants and regenerative dentistry products are developed. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| judges.uk.com | 2002 | London, United Kingdom | – | 622 | Acquisition and development of scientific instrument businesses is conducted. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. |
Detailed similar companies of L2MTech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cardiac and Vascular Disorders
10 companies that operate in the same segment as L2MTech (Cardiac and Vascular Disorders), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Connected devices for health, sleep, and activity monitoring are developed. | 2008 | Moulineaux, Seine-maritime, France | USD 93.83 M | – | – | |
SMT is recognized as a developer of cardiovascular medical devices. | 1998 | Surat, Gujarat, India | – | USD 106.25 M | 1,090 | |
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | – | 255 | |
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 | |
Cloud-based ambulatory ECG monitors for cardiac arrhythmia diagnosis are provided. | 2006 | San Francisco, California, United States | USD 109.23 M | USD 747.14 M | 2,000 | |
Provider of neuroprotection devices for carotid artery disease | 2007 | Sunnyvale, California, United States | USD 241.8 M | – | – | |
Miniaturized wireless implantable sensors are developed for hemodynamic monitoring. | 2007 | East Peoria, Illinois, United States | USD 154.77 M | – | 104 | |
Access catheters for neurovascular stroke treatment are provided. | 2015 | Campbell, California, United States | USD 596 M | – | – | |
Biosensor patches are developed for monitoring multiple body vitals. | 2011 | Campbell, California, United States | USD 239.95 M | – | 184 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about L2MTech
L2MTech was founded in 2017.
L2MTech is headquartered in Bonn, Germany. It is registered at Bonn, North Rhine-westphalia, Germany.
The primary company behind L2MTech, L2mtech India Private Limited, reported revenue of ₹88.9 Lakh for FY 2024, down 55% year on year.
L2MTech GmbH is a multinational company based in Bonn, Germany, specializing in designing, developing, manufacturing, and distributing medical devices. They focus on products such as stents and catheters for treating peripheral artery disease and other cardiovascular conditions. The company serves healthcare establishments worldwide through B2B channels, emphasizing innovative solutions for medical interventions.
L2MTech's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
L2MTech offers PearlFlow, LimusTrack, FlexiTrack-018 PTA Catheter, FlexiTrack-035 PTA Catheter, and 2 more products and services.
L2MTech operates through L2mtech India Private Limited.
The legal entities of L2MTech currently have 3 directors, including Raj Kumar Mamtani, Lalit Mamtani, Mahek Mamtani.